Clovis sales rebound in Q3

BOULDER — Clovis Oncology Inc. (Nasdaq: CLVS) beat analyst expectations in its third quarter earnings after a brutal early Q2 pummeled its stock price.

The Boulder cancer treatment company posted revenues of $37.6 million for the quarter and a loss of $1.72 per share, according to filings with the U.S. Securities and Exchange Commission this morning. Those figures beat Wall Street consensus estimates by $1.76 million and 17 cents of additional loss per share, according to Seeking Alpha data.

It took a net loss of $94.07 million in the quarter, but reduced its cash burn rate 42 percent from the past quarter to settle at $45 million. That reduction was partially due to decreased milestone payments from Clovis to collaborators and taking in payments from a joint Phase III trial.

SPONSORED CONTENT

People Powered: Preparing Longmont Businesses for Economic Success

Longmont Chamber and FNBO present People Powered on April 24, 2024, aiming to inform business owners about workforce development, housing, and transportation issues.

The company’s stock was battered in August from its last earnings report, where it posted a $120.9 million net loss and missed earnings per share estimates by 56 cents.

The poor results were followed by the announcement of what would become a $263 million off-market fundraising round to refinance debts and as a cash infusion, warding off investor thoughts that Clovis could be an attractive acquisition target in an active year for pharmaceutical mergers and takeovers. Pfizer Inc. (NYSE: PFE) spread its merger might into the Boulder Valley earlier this year, closing on an $11 billion takeover of Array Biopharma Inc.

Those two events drove Clovis stock down 46 percent in the span of a few days, but regained over the past quarter after large invests from Vanguard Group Inc. and Citadel Advisors LLC.

Clovis stock shot up 24 percent on the pre-market results before falling to a 16 percent gain on the day as of 9:30 a.m. Mountain Time at $4.17 per share.